A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

Author： Wierzbicki Rafal   Jonker Derek   Moore Malcolm   Berry Scott   Loehrer Patrick   Youssoufian Hagop   Rowinsky Eric  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.29, Iss.1, 2011-02, pp. : 167-174

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status

By Kang Myoung  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1607-1613

Springer Publishing Company

Access to resources Recommend Favorite

A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer

By MacKenzie Mary   Hirte Holger   Glenwood Goss   Jean Maroun   Goel Rakesh   Major Pierre   Miller Jr. Wilson   Panasci Lawrence   Lorimer Ian   Batist Gerald   Matthews Sarah   Douglas Lynn   Seymour Lesley  

Investigational New Drugs, Vol. 23, Iss. 2, 2005-01 ,pp. : 165-170

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

By Shitara Kohei  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 787-793

Springer Publishing Company

Access to resources Recommend Favorite

A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma

By Kefford Richard   Beith Jane   Hazel Guy   Millward Michael   Trotter James   Wyld David   Kusic Rada   Shreeniwas Revati   Morganti Adele   Ballmer Andrea   Segal Eleonor   Nayler Oliver   Clozel Martine  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 247-252

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors

By  

Current Cancer Drug Targets, Vol. 7, Iss. 7, 2007-11 ,pp. : 666-673

Bentham Science Publishers

Access to resources Recommend Favorite